Correlation between the expression levels of miR-1 and PIK3CA in non-small-cell lung cancer and their relationship with clinical characteristics and prognosis

Future Oncology

Volumn 10, Issue 1, 2014, Pages 49-57

  Zhao, Qiu ^a   Zhang, Bin ^a   Shao, Yongfeng ^a   Chen, Liang ^a   Wang, Xuanyi ^a   Zhang, Zhihong ^a   Shu, Yongqian ^a   Guo, Renhua ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

metastasis; miR 1; non small cell lung cancer; PIK3CA; recurrence

Indexed keywords

MICRORNA 1; PIK3CA PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; MICRORNA; MIRN1 MICRORNA, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; CARCINOMA, NON-SMALL-CELL LUNG; GENE EXPRESSION REGULATION; GENETICS; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; REFERENCE VALUE; TUMOR RECURRENCE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PHOSPHATIDYLINOSITOL 3-KINASES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REFERENCE VALUES;

EID: 84902175980     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.242     Document Type: Article

References (39)

1. Ramalingam S, Pawlish K, Gadgeel S et al. Lung cancer in young patients: analysis of a surveillance, epidemiology, and end results database. J. Clin. Oncol. 16, 651-657 (1998).
2. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J. Clin. 59, 225-249 (2009).
3. Uramoto H, Tanaka F. Prediction of recurrence after complete resection in patients with NSCLC. Anticancer Res. 32, 3953-3960 (2012).
4. Tanvetyanon T, Robinson L, Sommers KE et al. Relationship between tumor size and survival among patients with resection of multiple synchronous lung cancers. J. Thorac. Oncol. 5, 1018-1024 (2010).
5. Maeda R, Yoshida J, Ishii G et al. Risk factors for tumor recurrence in patients with early-stage (stage I and II) non-small cell lung cancer: patient selection criteria for adjuvant chemotherapy according to the seventh edition TNM classification. Chest 140, 1494-1502 (2011).
6. Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. Nat. Rev. Mol. Cell Biol. 6, 376-385 (2005).
7. Mourelatos Z, Dostie J, Paushkin S et al. miRNPs: a novel class of ribonucleoproteins containing numerous microRNAs. Genes Dev. 16, 720-728 (2002).
8. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science 294, 853-858 (2001).
9. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281-297 (2004).
10. Volinia S, Calin GA, Liu CG et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl Acad. Sci. USA 103, 2257-2261 (2006).
11. Lu J, Getz G, Miska EA et al. MicroRNA expression profiles classify human cancers. Nature 435, 834-838 (2005).
12. Volinia S, Galasso M, Costinean S et al. Reprogramming of miRNA networks in cancer and leukemia. Genome Res. 20, 589-599 (2010).
13. Ozen M, Creighton CJ, Ozdemir M et al. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 27, 1788-1793 (2008).
14. Iorio MV, Ferracin M, Liu CG et al. MicroRNA gene expression, deregulation in human breast cancer. Cancer Res. 65, 7065-7070 (2005).
15. Zhang B, Pan X, Cobb GP et al. microRNAs as oncogenes and tumor suppressors. Dev. Biol. 302, 1-12 (2007).
16. Marton S, Garcia MR, Robello C et al. A small RNAs analysis in CLL reveals a deregulation of miRNA expression and novel miRNA candidates of putative relevance in CLL pathogenesis. Leukemia 22, 330-338 (2008).
17. Eder M, Scherr M. MicroRNA and lung cancer. N. Engl. J. Med. 352, 2446-2448 (2005).
18. Yang B, Lin H, Xiao J et al. The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat. Med. 13, 486-491 (2007).
19. Mishima Y, Abreu-Goodger C, Staton AA et al. Zebrafish miR-1 and miR-133 shape muscle gene expression and regulate sarcomeric actin organization. Genes Dev. 23, 619-632 (2009).
20. Volinia S, Galasso M, Costinean S et al. Reprogramming of miRNA networks in cancer and leukemia. Genome Res. 20, 589-599 (2010).
21. Chen JF, Mandel EM, Thomson JM et al. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat. Genet. 38, 228-233 (2006).
22. Navon R, Wang H, Steinfeld I et al. Novel rank-based statistical methods reveal microRNAs with differential expression in multiple cancer types. PLoS One 4, e8003 (2009).
23. Nasser MW, Datta J, Nuovo G et al. Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J. Biol. Chem. 283, 33394-33405 (2008).
24. Datta J, Kutay H, Nasser MW et al. Methylation mediated silencing of microRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res. 68, 5049-5058 (2008).
25. Hu Z, Chen X, Zhao Y et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J. Clin. Oncol. 28, 1721-1726 (2010).
26. Massion PP, Kuo WL, Stokoe D et al. Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway. Cancer Res. 62, 3636-3640 (2002).
27. Vanhaesebroeck B, Stein RC, Waterfield MD. The study of phosphoinositide 3-kinase function. Cancer Surv. 27, 249-270 (1996).
28. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer 2, 489-501 (2002).
29. Trigka EA, Levidou G, Saetta AA et al. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features. Oncol. Rep. 30, 623-636 (2013).
30. Ogino S, Lochhead P, Giovannucci E, Meyerhardt JA, Fuchs CS, Chan AT. Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology. Oncogene doi:10.1038/onc.2013.244 (2013) (Epub ahead of print).
31. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25, 402-408 (2001).
32. Yan D, Dong Xda E, Chen X et al. MicroRNA-1/206 targets c-Met and inhibits rhabdomyosarcoma development. J. Biol. Chem. 284, 29596-29604 (2009).
33. Hudson RS, Yi M, Esposito D et al. MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer. Nucleic Acids Res. 40, 3689-3703 (2012).
34. Ding L, Getz G, Wheeler DA et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455, 1069-1075 (2008).
35. Fidler MJ, Morrison LE, Basu S et al. PTEN and PIK3CA gene copy numbers and poor outcomes in non-small cell lung cancer patients with gefitinib therapy. Br. J. Cancer 105, 1920-1926 (2011).
36. Kawano O, Sasaki H, Endo K et al. PIK3CA mutation status in Japanese lung cancer patients. Lung Cancer 54, 209-215 (2006).
37. Okudela K, Suzuki M, Kageyama S et al. PIK3CA mutation and amplification in human lung cancer. Pathol. Int. 579, 664-671 (2007).
38. Samuels Y, Wang Z, Bardelli A et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 23, 304, 554 (2004).
39. Björkqvist AM, Husgafvel-Pursiainen K, Anttila S et al. DNA gains in 3q occur frequently in squamous cell carcinoma of the lung, but not in adenocarcinoma. Genes Chromosomes Cancer 22, 79-82 (1998).